Kyverna Therapeutics (KYTX) Analyst & Key Data

Analyst Consensus

Buy6 analysts

Buy

Updated Sep 12, 2026

Total Analysts6

Buy

4

Ratings

Updated Sep 12, 2026

Overall Rating

C

DCF Score3.0 / 5

Debt / Equity Score3.0 / 5

Price / Book Score2.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$7.26

Median Target+285.67%

$28.00

Potential upside vs current price

DCF Value-71.87%

$2.04

Potential downside vs current price

Current Stock Price

$7.26

Median Target+285.67%

$28.00

Potential upside vs current price

DCF Value-71.87%

$2.04

Potential downside vs current price

Analyst Consensus

Buy6 analysts

Buy

Updated Sep 12, 2026

Total Analysts6

Buy

4

Ratings

Updated Sep 12, 2026

Overall Rating

C

DCF Score3.0 / 5

Debt / Equity Score3.0 / 5

Price / Book Score2.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$7.26

Median Target+285.67%

$28.00

Potential upside vs current price

DCF Value-71.87%

$2.04

Potential downside vs current price

Current Stock Price

$7.26

Median Target+285.67%

$28.00

Potential upside vs current price

DCF Value-71.87%

$2.04

Potential downside vs current price

Kyverna Therapeutics, Inc.